SCHEMBL5654948

SCHEMBL5654948

COC(CNCC1CCCCC1)OC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADH1B P00325 1/20 0.41
ADH1C P00326 1/20 0.41
ADH1A P07327 1/20 0.41
ADH4 P08319 1/20 0.41
ADH7 P40394 1/20 0.41
TDP1 Q9NUW8 1/20 0.39
HTT P42858 1/20 0.38
EPHX1 P07099 2/20 0.37
BCHE P06276 6/20 0.36
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
MMP1 P03956 1/20 0.35
MMP2 P08253 1/20 0.35
MMP3 P08254 1/20 0.35
MMP9 P14780 1/20 0.35
MMP8 P22894 1/20 0.35
CA9 Q16790 1/20 0.35
CHRM2 P08172 1/20 0.35
CHRM1 P11229 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12801233 0.98 ADH1B (0.38) ADH1BADH1CADH1AADH4ADH7
SCHEMBL2281448 0.90 SAT1 (0.38) TDP1KMT2A
SCHEMBL13483172 0.81 HTT (0.39) ADH1BADH1CADH1AADH4ADH7
SCHEMBL1775544 0.81 ADH1B (0.38) ADH1BADH1CADH1AADH4ADH7
SCHEMBL23224291 0.79 THRB (0.43)
SCHEMBL4670064 0.78 SIGMAR1 (0.44) EPHX1KMT2A
SCHEMBL12801292 0.78 SLC6A2 (0.34) KMT2A
SCHEMBL172616 0.77 ADH1B (0.45) ADH1BADH1CADH1AADH4ADH7
SCHEMBL9205347 0.76 CYP1A2 (0.36) ADH1BADH1CADH1AADH4ADH7
SCHEMBL4673810 0.76 SIGMAR1 (0.42) EPHX1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1511745-A4 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2006-11-15 EP disclosed
US-7109233-B2 Protease inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2006-09-19 US disclosed
EP-1532115-A4 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2006-01-11 EP disclosed
US-20050256100-A1 Protease inhibitors JEONG JAE U 2005-11-17 US disclosed
US-20050234038-A1 Protease inhibitors SMITHKLINE BEECHAM CORPORATION 2005-10-20 US disclosed
EP-1532115-A2 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-05-25 EP disclosed
EP-1511745-A2 PROTEASE INHIBITORS SmithKline Beecham Corporation (US) 2005-03-09 EP disclosed
WO-2003104257-A2 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-12-18 WO disclosed
WO-2003097593-A2 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234038-A1 Protease inhibitors SPINT2, CTRL, PRSS1 ADH1B 3736/4885ADH1C 4097/4885ADH1A 3516/4885
US-20050256100-A1 Protease inhibitors SPINT2, PRSS1, ADAM17 ADH1B 3154/4885ADH1C 3200/4885ADH1A 2505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.